Advertisement

Lupus erythematodes

  • Michael Sticherling
  • Annegret Kuhn
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Der Lupus erythematodes (LE) ist eine entzündliche Autoimmunerkrankung, die sich durch eine große klinische Heterogenität und variable Verläufe auszeichnet. Beim systemischen Lupus erythematodes (SLE) besteht die Möglichkeit der Entwicklung einer lebensbedrohlichen Beteiligung multipler Organe, die Haut, Bewegungsapparat, Nieren, kardiovaskuläres und zentralnervöses System betreffen kann. Auch kann sich die Erkrankung nur auf die Haut beschränken und wird dann als kutaner Lupus erythematodes (CLE) bezeichnet. Vor einem (immun)genetischen Hintergrund führen verschiedene Umweltfaktoren, wie Rauchen, Medikamente, Hormone, Infektionen und vor allem die ultraviolette (UV) Strahlung, zu einer Erstmanifestation oder Exazerbation der Erkrankung. Neue Erkenntnisse zur Pathogenese des CLE haben auch zu weiteren therapeutischen Optionen dieser Autoimmunerkrankung geführt.

Literatur

  1. Albrecht J, Taylor L, Berlin JA et al (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889–894CrossRefPubMedPubMedCentralGoogle Scholar
  2. Baima B, Sticherling M (2001) Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 144:958–966CrossRefPubMedGoogle Scholar
  3. Biazar C, Sigges J, Patsinakidis N et al (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444–454CrossRefPubMedGoogle Scholar
  4. Cancro MP, D’Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 19:1066–1073CrossRefGoogle Scholar
  5. Costner MI, Sontheimer RD, Provost TT (2003) Lupus erythematosus. In: Sontheimer RD, Provost TT (Hrsg) Cutaneous manifestations of rheumatic diseases. Williams & Wilkins, Philadelphia, S 15–64Google Scholar
  6. Crowson AN, Magro C (2001) The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 28:1–23CrossRefPubMedGoogle Scholar
  7. Dalle Vedove C, Simon JC, Girolomoni G (2012) Medikamenteninduzierter Lupus erythematodes unter besonderer Berücksichtigung von Hautmanifestationen und Anti-TNFα-Therapeutika. J Dtsch Dermatol Ges 10:889–897PubMedPubMedCentralGoogle Scholar
  8. Fischer-Betz R (2012) Rheumatische Erkrankungen in der Schwangerschaft. Internist (Berl) 53:1047–1053CrossRefGoogle Scholar
  9. Franceschini F, Cavazzana I (2005) Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38:55–63CrossRefPubMedGoogle Scholar
  10. Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930CrossRefPubMedPubMedCentralGoogle Scholar
  11. Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4:471–475CrossRefPubMedGoogle Scholar
  12. Jessop S, Whitelaw D, Jordaan F (2009) Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev (4):CD002954Google Scholar
  13. Kuhn A, Bonsmann G, Aberer E et al (2009) Leitlinien Kutaner Lupus Erythematosus (Entwicklungsstufe 1). In: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W (Hrsg) Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen, Bd 6. ABW Wissenschaftsverlag, Berlin, S 214–257Google Scholar
  14. Kuhn A, Amler S, Beissert S et al (2010) Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol 163:83–92PubMedGoogle Scholar
  15. Kuhn A, Ruland V, Bonsmann G (2010) Photosensitivity, phototesting and photoprotection in cutaneous lupus erythematosus. Lupus 19:1036–1046CrossRefPubMedGoogle Scholar
  16. Kuhn A, Ruland V, Bonsmann G (2011) Hautmanifestationen des Lupus erythematodes. Z Rheumatol 70:213–227CrossRefPubMedGoogle Scholar
  17. Kuhn A, Ruland V, Bonsmann G (2012) Cutaneous lupus erythematosus: update of therapeutic options Part I, II. J Am Acad Dermatol 65:e179–e193, e195–e213Google Scholar
  18. Kuhn A, Bonsmann G, Anders HJ et al (2015) Diagnose und Therapie des systemischen Lupus erythematodes. Dtsch Arztebl 112:423–432Google Scholar
  19. Kuhn A, Landmann A, Patsinakidis N et al (2016) Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study. Lupus 25:1357–1364CrossRefPubMedGoogle Scholar
  20. Kuhn A, Landmann A, Bonsmann G (2016) The skin in autoimmune diseases: unmet needs. Autoimmun Rev 15:948–954CrossRefPubMedGoogle Scholar
  21. Kuhn A, Wenzel J, Bijl M (2016) Lupus erythematosus revisited. Semin Immunopathol 38:97–112CrossRefPubMedGoogle Scholar
  22. Lee-Kirsch MA, Gong M, Schulz H et al (2006) Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 79:731–737CrossRefPubMedPubMedCentralGoogle Scholar
  23. Manzi S, Sanchez-Guerrero J, Merrill JT et al (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838CrossRefPubMedPubMedCentralGoogle Scholar
  24. Marmor MF, Kellner U, Lai TY et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123:1386–1394CrossRefPubMedGoogle Scholar
  25. Massone C, Kodama K, Salmhofer W et al (2005) Lupus erythemtaosus panniculitis (lupus profundus): clinical, histopathological and molecular analysis of nine cases. J Cutan Pathol 32:396–404CrossRefPubMedGoogle Scholar
  26. Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460CrossRefPubMedGoogle Scholar
  27. Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233CrossRefPubMedPubMedCentralGoogle Scholar
  28. Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 377:721–731CrossRefGoogle Scholar
  29. Ochsendorf FR (2010) Einsatz von Antimalariamitteln in der Dermatologie. J Dtsch Dermatol Ges 8:829–846PubMedGoogle Scholar
  30. Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefPubMedPubMedCentralGoogle Scholar
  31. Renner R, Sticherling M (2008) Incidental cases of subacute cutaneous lupus erythematosus in association with malignancy. Eur J Dermatol 18:700–704PubMedGoogle Scholar
  32. Renner R, Sticherling M (2009) The different faces of cutaneous lupus erythematosus. G Ital Dermatol Venereol 144:135–147PubMedGoogle Scholar
  33. Risselada AP, Kallenberg CG (2006) Therapy-resistant lupus skin disease successfully treated with rituximab. Rheumatology 45:915–916CrossRefPubMedGoogle Scholar
  34. Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–1226CrossRefPubMedGoogle Scholar
  35. Ruland V, Haust M, Stilling RM et al (2013) Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res (Hoboken) 65:767–776CrossRefGoogle Scholar
  36. Schmitt V, Meuth AM, Amler S et al (2010) Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 162:64–73CrossRefPubMedGoogle Scholar
  37. Shinada S, Wallace DJ (2004) Laboratory features of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (Hrsg) Cutaneous Lupus Erythematosus. Springer, Berlin, S 301–322Google Scholar
  38. Smith CD, Cyr M (1988) The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am 14:1–14PubMedGoogle Scholar
  39. Sontheimer RD, Henderson CL, Grau RH (2009) Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 301:65–70CrossRefPubMedGoogle Scholar
  40. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
  41. Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458–2466CrossRefPubMedGoogle Scholar
  42. Toberer F, Sykora J, Göttel D et al (2013) Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray. Exp Dermatol 22:656–659CrossRefPubMedGoogle Scholar
  43. Uthman I, Taher A, Abbas O et al (2008) Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 216:257–259CrossRefPubMedGoogle Scholar

Erstbeschreiber

  1. Bechet PE (1942) Lupus erythematodes hypertrophicus et profundus. Arch Derm Syphilol 45:33–39CrossRefGoogle Scholar
  2. Brocq L (1921) Précis-atlas de pratigue dermatologique. Doin, Paris, S 468–477Google Scholar
  3. Cazenave A, Schedel HE (1833) Abrégé pratique des maladies de la peau. 2ième ed. Béchet, Paris.Google Scholar
  4. Cazenave PLA (1851) Lupus érythemateaux (érythéme centrifuge). Ann Mal Peau Syph 3:297–299Google Scholar
  5. Gougerot H, Burnier R (1930) Lupus érythémateux tumidus. Bull Soc Fr Dermatol Syphiligr 37:1291–1292Google Scholar
  6. Hebra F (1845) Versuch einer auf pathologische Anatomie gegründeten Einteilung der Hautkrankheiten. K. K. Ges Aerzte Wien 1:34–52, 141–155, 211–231Google Scholar
  7. Hoffmann E (1909) Isolierter Lupus erythematodes tumidus der Gesichtshaut. Derm Z 16:159–160CrossRefGoogle Scholar
  8. Hutchinson J (1888) Harveian lectures on lupus. The varieties of common lupus. Br Med J 1:113–118CrossRefPubMedPubMedCentralGoogle Scholar
  9. Irgang S (1940) Lupus erythematosus profundus: report of an example with clinical resemblance to Darier-Roussy sarcoid. Arch Derm Syphilol 42:97–108CrossRefGoogle Scholar
  10. Kaposi MH (1872) Neue Beiträge zur Kenntnis des Lupus erythematosus. Arch Dermatol Syphilol 4:36–78CrossRefGoogle Scholar
  11. Kaposi M (1883) Pathologie und Therapie der Hautkrankheiten in Vorlesungen für praktische Ärzte und Studierende, 2. Aufl. Urban & Schwarzenberg, Wien, S 642Google Scholar
  12. McCustion CH, Schoch EP Jr (1954) Possible discoid lupus erythematosus in newborn infant; report of a case with subsequent development of acute systemic lupus erythematosus in mother. AMA Arch Derm Syphilol 70:782–785CrossRefGoogle Scholar
  13. O’Leary PA (1934) Disseminated lupus erythematosus. Minn Med 17:637–644Google Scholar
  14. Pedro SD, Dahl MV (1973) Direct immunofluorescence of bullous systemic lupus erythematosus. Arch Dermatol 107:118–120CrossRefPubMedGoogle Scholar
  15. Rowell NR, Beck S, Anderson JR (1963) Lupus erythematosus and erythema multiforme-like lesions. Arch Dermatol 88:176–180CrossRefPubMedGoogle Scholar
  16. Scholtz M (1922) Lupus erythematosus acutus disseminatus hemorrhagicus. Arch Dermatol Syph 6:466475Google Scholar
  17. Sontheimer RD, Thomas JR, Gilliam JN (1979) Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115:1409–1415CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Universitäts-HautklinikUniversitätsklinikum ErlangenErlangenDeutschland
  2. 2.Universitätsklinikum MünsterMünsterDeutschland

Section editors and affiliations

  • Michael Hertl
    • 1
  1. 1.Zentrum für HautkrankheitenMarburgDeutschland

Personalised recommendations